Telix Pharmaceuticals Limited (TLX)

Every figure this model derived for TLX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 25,692,000 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2025-12-31
cash 141,866,000 CashAndCashEquivalents 2025-12-31
current assets 330,280,000 CurrentAssets 2025-12-31
current liabilities 231,624,000 CurrentLiabilities 2025-12-31
equity 415,376,000 Equity 2025-12-31
interest expense 181,000 InterestExpense 2025-12-31
ocf -17,293,000 CashFlowsFromUsedInOperatingActivities 2025-12-31
revenue 803,794,000 RevenueFromContractsWithCustomers 2025-12-31
sbc 19,146,000 ExpenseFromSharebasedPaymentTransactionsWithEmployees 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up TLX on one particular measure came for.

RatioValue
cash operating margin8.76
current ratio1.43
current ratio reported1.43
dilution pct-2.12
ebit cagr64.41
ebit yoy-46.04
fcf margin-5.35
interest cover164.51
net debt ebitda6.6
operating margin3.7
owner earnings margin-7.73
revenue growth55.61
revenue growth per share58.98
roic3.12
rule of 4059.31
sbc pct revenue2.38

What to be careful about

What this model itself distrusts about TLX's figures. Written by the derivation as it ran, not added afterwards.